Human T-cell leukemia virus type I Tax genotype analysis in Okinawa, the southernmost and remotest islands of Japan: Different distributions compared with mainland Japan and the potential value for the prognosis of aggressive adult T-cell leukemia/lymphoma. (October 2017)

• Record Type: Journal Article
• Authors: Sakihama, Shugo; Saito, Mineki; Kuba-Miyara, Megumi; Tomoyose, Takeaki; Taira, Naoya; Miyagi, Takashi; Hayashi, Masaki; Kinjo, Shigeko; Nakachi, Sawako; Tedokon, Iori; Nishi, Yukiko; Tamaki, Keita; Morichika, Kazuho; Uchihara, Jun-nosuke; Morishima, Satoko; Karube, Ken-nosuke; Tanaka, Yuetsu; Masuzaki, Hiroaki; Fukushima, Takuya
• Is Part Of: Leukemia research. Volume 61(2017:Oct.)
• Page Start: 18
• Page End: 24
• Publication Date: 2017-10
• Subjects: HTLV-1 -- tax Genotype -- Okinawa -- Aggressive ATL -- Prognostic factor; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2017.08.006
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: The HTLV-1 genotype distributions in Okinawa differs from that in mainland Japan. The prognosis of aggressive ATL patients with tax A is poorer than those with taxB . HTLV-1 Tax genotype has potential value as a prognostic factor for aggressive ATL. Abstract: Okinawa, comprising remote islands off the mainland of Japan, is an endemic area of human T-cell leukemia virus type I (HTLV-1), the causative virus of adult T-cell leukemia-lymphoma (ATL) and HTLV-1-associated myelopathy (HAM). We investigated the tax genotype of HTLV-1 among 29 HTLV-1 carriers, 74 ATL patients, and 33 HAM patients in Okinawa. The genotype distribution—60 (44%) tax A cases and 76 (56%) tax B cases—differed from that of a previous report from Kagoshima Prefecture in mainland Japan ( tax A, 10%; tax B, 90%). A comparison of the clinical outcomes of 45 patients ( tax A, 14; tax B, 31) with aggressive ATL revealed that the overall response and 1-year overall survival rates for tax A (50% and 35%, respectively) were lower than those for tax B (71% and 49%, respectively). In a multivariate analysis of two prognostic indices for aggressive ATL, Japan Clinical Oncology Group-Prognostic Index and Prognostic Index for acute and lymphoma ATL, with respect to age, performance status, corrected calcium, soluble interleukin-2 receptor, and tax genotype, the estimated hazard ratio of tax A compared with tax B was 2.68 (95% confidence interval, 0.87–8.25; P = 0.086). Our results suggest that the tax genotype has clinical value as a prognostic factor for aggressive ATL.